Harlan A Pinto, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pinto’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G63197 · Current
Licensed to practise in California · since 1988 · expires 2028-04-30 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$37,445
Medicare paid this office $37,445 for 88 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 54 | $21,603 | $123 |
| New patient visit (60+ min) | 30 | $4,874 | $162 |
| Return visit (30+ min) | 29 | $4,445 | $81 |
| Long return visit (40+ min) | 13 | $2,379 | $159 |
| Return visit (30+ min) | 12 | $2,226 | $124 |
See all 6 services
| Long return visit (40+ min) | 54 | $21,603 | $123 |
| New patient visit (60+ min) | 30 | $4,874 | $162 |
| Return visit (30+ min) | 29 | $4,445 | $81 |
| Long return visit (40+ min) | 13 | $2,379 | $159 |
| Return visit (30+ min) | 12 | $2,226 | $124 |
| Diagnostic exam of voice box using a flexible endoscope | 12 | $921 | $51 |
Who their Medicare patients are
88 Original Medicare patients in 2024. Average age 74 · Women 31% · Also on Medicaid 13% · Health risk score 2.26. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 68% · Coronary heart disease 26% · Atrial fibrillation 26% · Chronic kidney disease 24% · Diabetes 22% · Cancer 19% · Depression 17% · Heart failure 14%.
The office billed $83,602, Medicare allowed $49,510 and paid $37,445; for 336 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 88 | 336 | 74 | 2.26 | $83,602 | $37,445 |
| 2023 | 97 | 409 | 75 | 2.42 | $101,788 | $44,484 |
| 2022 | 80 | 451 | 74 | 2.62 | $92,063 | $51,334 |
| 2021 | 87 | 481 | 74 | 2.57 | $106,901 | $54,109 |
| 2020 | 81 | 474 | 72 | 2.38 | $84,544 | $37,557 |
| 2019 | 79 | 223 | 72 | 2.19 | $29,654 | $18,147 |
| 2018 | 81 | 418 | 71 | 2.49 | $46,007 | $28,750 |
| 2017 | 105 | 452 | 72 | 1.79 | $80,748 | $31,810 |
| 2016 | 81 | 310 | 72 | 2.11 | $61,510 | $21,330 |
| 2015 | 89 | 390 | 73 | 2.04 | $78,531 | $26,901 |
| 2014 | 62 | 313 | 72 | 2.11 | $60,434 | $20,384 |
| 2013 | 56 | 232 | 70 | 1.92 | $45,531 | $14,672 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 63 | $24,711 | $127 |
| Return visit (30+ min) | 52 | $12,834 | $87 |
| New patient visit (60+ min) | 23 | $3,674 | $160 |
2022: 3 services
| Long return visit (40+ min) | 59 | $38,290 | $126 |
| Return visit (30+ min) | 45 | $8,387 | $83 |
| New patient visit (60+ min) | 17 | $2,868 | $169 |
2021: 4 services
| Long return visit (40+ min) | 62 | $32,475 | $131 |
| Return visit (30+ min) | 53 | $15,390 | $92 |
| New patient visit (60+ min) | 18 | $3,137 | $174 |
| Short return visit (20+ min) | 13 | $1,340 | $56 |
2020: 4 services
| Return visit (30+ min) | 58 | $18,414 | $71 |
| Long return visit (40+ min) | 40 | $11,032 | $103 |
| New patient visit (60+ min) | 22 | $3,458 | $157 |
| Short return visit (20+ min) | 22 | $2,316 | $46 |
2019: 5 services
| Return visit (30+ min) | 51 | $7,966 | $71 |
| Long return visit (40+ min) | 27 | $4,442 | $101 |
| New patient visit (60+ min) | 20 | $3,046 | $152 |
| Diagnostic exam of voice box using a flexible endoscope | 21 | $1,474 | $61 |
| Short return visit (20+ min) | 12 | $789 | $46 |
2018: 5 services
| Return visit (30+ min) | 60 | $15,820 | $66 |
| Long return visit (40+ min) | 34 | $5,505 | $97 |
| Short return visit (20+ min) | 28 | $3,230 | $43 |
| New patient visit (60+ min) | 16 | $2,265 | $142 |
| Diagnostic exam of voice box using a flexible endoscope | 16 | $1,183 | $54 |
2017: 6 services
| Return visit (30+ min) | 56 | $16,131 | $67 |
| New patient visit (60+ min) | 27 | $3,915 | $145 |
| Short return visit (20+ min) | 34 | $3,837 | $43 |
| Long return visit (40+ min) | 20 | $3,686 | $95 |
| New patient visit (45+ min) | 16 | $1,848 | $116 |
| Diagnostic exam of voice box using a flexible endoscope | 14 | $1,392 | $63 |
2016: 6 services
| Return visit (30+ min) | 47 | $9,928 | $66 |
| Short return visit (20+ min) | 29 | $3,031 | $43 |
| New patient visit (60+ min) | 16 | $2,396 | $150 |
| Long return visit (40+ min) | 18 | $2,101 | $96 |
| New patient visit (45+ min) | 16 | $1,846 | $115 |
| Diagnostic exam of voice box using a flexible endoscope | 17 | $1,362 | $62 |
2015: 5 services
| Return visit (30+ min) | 52 | $13,883 | $67 |
| Short return visit (20+ min) | 32 | $3,645 | $44 |
| New patient visit (60+ min) | 23 | $3,447 | $150 |
| Long return visit (40+ min) | 14 | $2,484 | $99 |
| Diagnostic exam of voice box using a flexible endoscope | 15 | $1,125 | $70 |
2014: 4 services
| Return visit (30+ min) | 43 | $11,586 | $67 |
| Short return visit (20+ min) | 31 | $3,685 | $44 |
| New patient visit (60+ min) | 16 | $2,163 | $135 |
| Diagnostic exam of voice box using a flexible endoscope | 16 | $1,500 | $68 |
2013: 3 services
| Return visit (30+ min) | 41 | $8,460 | $63 |
| Short return visit (20+ min) | 26 | $2,456 | $42 |
| New patient visit (60+ min) | 13 | $1,887 | $145 |
Drugs they prescribed that Part D paid
$151,200
Pharmacies billed $151,200 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (19 of 229) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 63% of their opioid prescriptions.
192 generic and fewer than 11 brand-name prescriptions · $151,200 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pentoxifylline | 12 | $482 | $40 |
| Morphine Sulfate Er | 12 | $239 | $20 |
| Levothyroxine | 20 | $185 | $9 |
| Ondansetron | 21 | $156 | $7 |
| Prochlorperazine Maleate | 13 | $125 | $10 |
See all 8 drugs
| Pentoxifylline | 12 | $482 | $40 |
| Morphine Sulfate Er | 12 | $239 | $20 |
| Levothyroxine | 20 | $185 | $9 |
| Ondansetron | 21 | $156 | $7 |
| Prochlorperazine Maleate | 13 | $125 | $10 |
| Chlorhexidine Gluconate | 13 | $94 | $7 |
| Omeprazole | 12 | $40 | $3 |
| Lorazepam | 11 | $26 | $2 |
Year by year
| 2024 | 229 | 39 | 8% (19) | None | $151,200 |
| 2023 | 360 | 47 | 7% (25) | None | $320,959 |
| 2022 | 144 | 30 | 8% (12) | 17% | $270,060 |
| 2021 | 117 | 23 | None | 25% | $312,690 |
| 2020 | 203 | 37 | 5% (11) | 11% | $148,996 |
| 2019 | 79 | 22 | None | 15% | $2,718 |
| 2018 | 108 | 21 | None | None | $166,946 |
| 2017 | 151 | 26 | None | 15% | $82,960 |
| 2016 | 139 | 29 | 12% (16) | 12% | $11,130 |
| 2015 | 189 | 28 | 9% (17) | None | $98,340 |
| 2014 | 213 | 25 | 10% (21) | None | $73,239 |
| 2013 | 150 | 21 | 11% (17) | None | $35,572 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Morphine Sulfate Er | 11 | $852 | $77 |
| Levothyroxine | 32 | $574 | $18 |
| Ondansetron | 35 | $449 | $13 |
| Prochlorperazine Maleate | 37 | $379 | $10 |
| Omeprazole | 18 | $291 | $16 |
| Pentoxifylline | 11 | $182 | $17 |
| Lorazepam | 20 | $162 | $8 |
| Meloxicam | 12 | $142 | $12 |
| Metoclopramide | 11 | $48 | $4 |
2022: 2 drugs
| Ondansetron | 20 | $2,970 | $148 |
| Prochlorperazine Maleate | 14 | $179 | $13 |
2020: 5 drugs
| Doxycycline Hyclate | 13 | $715 | $55 |
| Levothyroxine | 26 | $544 | $21 |
| Dexamethasone | 23 | $342 | $15 |
| Ondansetron | 20 | $241 | $12 |
| Prochlorperazine Maleate | 18 | $204 | $11 |
2019: 2 drugs
| Dexamethasone | 15 | $227 | $15 |
| Levothyroxine | 11 | $212 | $19 |
2018: 2 drugs
| Prochlorperazine Maleate | 11 | $69 | $6 |
| Lorazepam | 13 | $67 | $5 |
2017: 1 drug
| Levothyroxine | 12 | $272 | $23 |
2016: 5 drugs
| Lorazepam | 20 | $147 | $7 |
| Ondansetron | 12 | $127 | $11 |
| Prochlorperazine Maleate | 15 | $112 | $7 |
| Dexamethasone | 12 | $103 | $9 |
| Metoclopramide | 12 | $57 | $5 |
2015: 4 drugs
| Clindamycin Phosphate | 14 | $2,123 | $152 |
| Gabapentin | 17 | $676 | $40 |
| Ondansetron | 16 | $346 | $22 |
| Dexamethasone | 18 | $106 | $6 |
2014: 5 drugs
| Clindamycin Phosphate | 11 | $1,812 | $165 |
| Famciclovir | 11 | $841 | $76 |
| Hydrocodone-Acetaminophen | 14 | $371 | $27 |
| Dexamethasone | 19 | $135 | $7 |
| Lorazepam | 19 | $111 | $6 |
2013: 3 drugs
| Hydrocodone-Acetaminophen | 16 | $536 | $34 |
| Levothyroxine | 17 | $107 | $6 |
| Lorazepam | 14 | $79 | $6 |
Money from drug and device companies
$148 in 2019
A payment is not proof that care is biased.
| Tactile Systems Technology | Flexitouch | $148 | 1 payment
|
See the published payment
| Tactile Systems Technology | Meals · 2019-02-20 | Flexitouch | $148 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1194813956
- Licence
- CA G63197California G63197: Current · expires 2028-04-30
- Trained
- Yale University School of Medicine, 1983
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-10-10
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur Dr, Palo Alto, CA, 94304